Predictive Oncology Faces Delisting Concerns

TL;DR

Predictive Oncology might get kicked off the exchange. Big trouble.

AI Summary

Predictive Oncology Inc. filed an 8-K on November 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Skyline Medical Inc., is based in Pittsburgh, PA.

Why It Matters

This filing indicates potential issues with the company's stock exchange listing, which could impact its liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• November 22, 2024 (date) — Date of earliest event reported
• Skyline Medical Inc. (company) — Former company name
• Pittsburgh, PA (location) — Business and mailing address

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market
• $1,966,969 — e the Company's stockholders' equity of $1,966,969, as reported in the Company's Quarterly
• $2.5 m — 2024, was below the required minimum of $2.5 million, and because, as of the date of t
• $35 million — value of listed securities of at least $35 million or net income from continuing operation
• $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y

Filing Documents

• f8k_112224.htm (8-K) — 27KB
• 0001171843-24-006536.txt ( ) — 197KB
• poai-20241122.xsd (EX-101.SCH) — 3KB
• poai-20241122_lab.xml (EX-101.LAB) — 33KB
• poai-20241122_pre.xml (EX-101.PRE) — 22KB
• f8k_112224_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2024, Predictive Oncology Inc. (the "Company") received a letter (the "Notice) from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), because the Company's stockholders' equity of $1,966,969, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, was below the required minimum of $2.5 million, and because, as of the date of the Notice (and as of the date of this report), the Company did not meet either of the alternative compliance standards, relating to market value of listed securities of at least $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective, subject to the Company's compliance with the other continued listing requirements, and the Company's regaining compliance with the Stockholders' Equity Requirement. Under Nasdaq rules and as specified in the Notice, the Company has 45 calendar days from November 20, 2024, or until Monday, January 6, 2025 to submit to Nasdaq a plan to regain compliance with the Stockholders' Equity Requirement. If the Company's plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to evidence compliance. The Company is presently evaluating various courses of action to regain compliance and intends to

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: November 22, 2024 By: /s/ Josh Blacher Josh Blacher Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR